The pharmacokinetics of enalapril in patients with compensated liver cirrhosis.
The possibility of an impaired hepatic de-esterification of enalapril to enalaprilat due to hepatic dysfunction was assessed in seven patients with compensated liver cirrhosis and 10 normal control subjects. The peak serum concentration and time to the peak serum concentration of enalaprilat, as well as the suppression of serum angiotensin converting enzyme activity, following a single oral dose of enalapril maleate (10 mg) were not different in the two groups. The elimination half-life of enalaprilat was related to renal function. The results suggest that hepatic biotransformation of the drug may not be disturbed in a clinically significant manner in patients with moderate hepatic dysfunction due to compensated liver cirrhosis.
Baba
T
T
Third Department of Internal Medicine, Hirosaki University School of Medicine, Japan.
Murabayashi
S
S
Tomiyama
T
T
Takebe
K
K
D000328:Adult; D004656:Enalapril / Q000493:pharmacokinetics*; D015773:Enalaprilat / Q000493:pharmacokinetics; D006207:Half-Life; D006801:Humans; D008103:Liver Cirrhosis / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism; D011863:Radioimmunoassay
D004656:Enalapril; D007703:Peptidyl-Dipeptidase A; D015773:Enalaprilat